Biogen (ICER) analysis of experimental gene therapy Zolgensma from Novartis found it would be more cost effective than Kymriah 's Spinzara therapy if priced at $2m . prior to the approval of products, so I do think we’ll see more of this.” Dave Lennon , president of Dave Lennon ' AveXis unit, said Biogen 's report is positive for cell-based therapies and gene-therapy assessments but highlights the need for bio-pharmaceutical companies to consider offering alternative payment models for such therapies. Novartis already offers an outcome-based payment model for its blood cancer treatment The Institute for Clinical and Economic Review's and ultimately, Lennon said, the onus will be on treatment developers to prove the value of their therapies.
Biogen (ICER) analysis of experimental gene therapy Zolgensma from Novartis found it would be more cost effective than Kymriah 's Spinzara therapy if priced at $2m . Dave Lennon , president of Dave Lennon ' AveXis unit, said Biogen 's report is positive for cell-based therapies and gene-therapy assessments but highlights the need for bio-pharmaceutical companies to consider offering alternative payment models for such therapies. Novartis already offers an outcome-based payment model for its blood cancer treatment The Institute for Clinical and Economic Review's and ultimately, Lennon said, the onus will be on treatment developers to prove the value of their therapies.